NO20032441D0 - Kombinasjon av GABA agonister og sorbitol-dehydrogenase inhibitorer - Google Patents

Kombinasjon av GABA agonister og sorbitol-dehydrogenase inhibitorer

Info

Publication number
NO20032441D0
NO20032441D0 NO20032441A NO20032441A NO20032441D0 NO 20032441 D0 NO20032441 D0 NO 20032441D0 NO 20032441 A NO20032441 A NO 20032441A NO 20032441 A NO20032441 A NO 20032441A NO 20032441 D0 NO20032441 D0 NO 20032441D0
Authority
NO
Norway
Prior art keywords
combination
dehydrogenase inhibitors
sorbitol dehydrogenase
gaba agonists
gaba
Prior art date
Application number
NO20032441A
Other languages
English (en)
Other versions
NO20032441L (no
Inventor
Banavara Lakshman Mylari
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20032441D0 publication Critical patent/NO20032441D0/no
Publication of NO20032441L publication Critical patent/NO20032441L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20032441A 2000-11-30 2003-05-28 Kombinasjon av GABA agonister og sorbitol-dehydrogenase inhibitorer NO20032441L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25006900P 2000-11-30 2000-11-30
PCT/IB2001/002213 WO2002043762A2 (en) 2000-11-30 2001-11-19 Combination of gaba agonists and sorbitol dehydrogenase inhibitors

Publications (2)

Publication Number Publication Date
NO20032441D0 true NO20032441D0 (no) 2003-05-28
NO20032441L NO20032441L (no) 2003-07-03

Family

ID=22946187

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032441A NO20032441L (no) 2000-11-30 2003-05-28 Kombinasjon av GABA agonister og sorbitol-dehydrogenase inhibitorer

Country Status (38)

Country Link
US (1) US6544998B2 (no)
EP (1) EP1337271B1 (no)
JP (1) JP2004514699A (no)
KR (1) KR20030059290A (no)
CN (1) CN1477975A (no)
AP (1) AP2001002360A0 (no)
AR (1) AR031431A1 (no)
AT (1) ATE281181T1 (no)
AU (1) AU2002215159A1 (no)
BG (1) BG107774A (no)
BR (1) BR0115783A (no)
CA (1) CA2430298A1 (no)
CR (1) CR6964A (no)
CZ (1) CZ20031399A3 (no)
DE (1) DE60106968T2 (no)
DO (1) DOP2001000289A (no)
EA (1) EA200300432A1 (no)
EC (1) ECSP034624A (no)
EE (1) EE200300248A (no)
ES (1) ES2230378T3 (no)
HR (1) HRP20030420A2 (no)
HU (1) HUP0302160A3 (no)
IL (1) IL155704A0 (no)
IS (1) IS6786A (no)
MA (1) MA26964A1 (no)
MX (1) MXPA03004870A (no)
NO (1) NO20032441L (no)
OA (1) OA12534A (no)
PA (1) PA8534101A1 (no)
PE (1) PE20020597A1 (no)
PL (1) PL365927A1 (no)
PT (1) PT1337271E (no)
SK (1) SK6192003A3 (no)
SV (1) SV2003000751A (no)
TN (1) TNSN01169A1 (no)
UY (1) UY27042A1 (no)
WO (1) WO2002043762A2 (no)
ZA (1) ZA200303381B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126999A (en) 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
US7022678B2 (en) * 2001-03-30 2006-04-04 Warner-Lambert Company Pregabalin lactose conjugates
SK286227B6 (sk) * 2001-05-25 2008-05-06 Warner-Lambert Company Llc Kvapalná farmaceutická kompozícia obsahujúca analóg GABA a spôsob jej prípravy a použitie
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
KR20050036195A (ko) * 2003-10-15 2005-04-20 고재영 신규한 망막병증 치료제 조성물
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
WO2005097079A2 (en) * 2004-04-02 2005-10-20 Impax Laboratories, Inc. Controlled release dosage for gaba receptor agonist
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
ES2528674T3 (es) 2005-02-17 2015-02-11 Astellas Pharma Inc. Piperidina y carboxilatos de piperacina como inhibidores de FAAH
GB0513553D0 (en) * 2005-07-01 2005-08-10 Fond D Amico Per La Ricerca Su Rab3a
DK2142529T3 (da) 2007-04-27 2014-02-10 Purdue Pharma Lp Trpv1-antagonister og anvendelser deraf
WO2009046801A1 (en) * 2007-10-09 2009-04-16 Merck Patent Gmbh Pharmaceutical compositions containing benfotiamine and one or one more pharmaceutically active agents for the treatment of pain conditions of neuropathic origin
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
EP2509596B1 (en) 2009-12-08 2019-08-28 Case Western Reserve University Gamma aminoacids for treating ocular disorders
WO2012050907A2 (en) * 2010-09-28 2012-04-19 The Regents Of The University Of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
HRP20170507T1 (hr) 2011-06-22 2017-06-02 Purdue Pharma Lp Trpv1 antagonisti uključujući dihidroksi supstituente i njihove uporabe
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
WO2020227430A1 (en) * 2019-05-07 2020-11-12 University Of Miami Treatment and detection of inherited neuropathies and associated disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2409754A (en) 1946-10-22 Method for obtaining hydantoins
CH449645A (de) 1963-07-09 1968-01-15 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
CH427803A (de) 1963-12-06 1967-01-15 Geigy Ag J R Verfahren zur Herstellung eines neuen Isoxazolderivates
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US3960927A (en) 1975-03-18 1976-06-01 Richardson-Merrell Inc. Olefinic derivatives of amino acids
FR2319338A1 (fr) * 1975-08-01 1977-02-25 Synthelabo Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent
DD151309A5 (de) 1979-06-01 1981-10-14 Wellcome Found Verfahren zur herstellung von substituierten aminotriazinen
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
DK288385D0 (da) 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5728704A (en) * 1992-09-28 1998-03-17 Pfizer Inc. Substituted pyridmidines for control of diabetic complications
AU3503300A (en) * 1999-02-24 2000-09-14 Regents Of The University Of California, The Gaba receptors mediate inhibition of t cell responses
AP2005003199A0 (en) * 1999-04-01 2005-03-31 Pfizer Prod Inc Aminopyrimidines as sorbitol dehydrogenase inhibitors
DE60009777T2 (de) * 1999-04-01 2004-08-19 Pfizer Products Inc., Groton Verbindung für Behandlung und Vorsorge bei Diabetes

Also Published As

Publication number Publication date
MXPA03004870A (es) 2003-08-19
MA26964A1 (fr) 2004-12-20
PE20020597A1 (es) 2002-07-08
JP2004514699A (ja) 2004-05-20
BR0115783A (pt) 2003-09-16
PA8534101A1 (es) 2002-10-31
PT1337271E (pt) 2005-01-31
TNSN01169A1 (fr) 2005-11-10
CR6964A (es) 2004-02-02
IL155704A0 (en) 2003-11-23
KR20030059290A (ko) 2003-07-07
IS6786A (is) 2003-04-14
US6544998B2 (en) 2003-04-08
AU2002215159A1 (en) 2002-06-11
ECSP034624A (es) 2003-07-25
DE60106968D1 (de) 2004-12-09
US20020091128A1 (en) 2002-07-11
CN1477975A (zh) 2004-02-25
EP1337271B1 (en) 2004-11-03
CZ20031399A3 (cs) 2004-04-14
CA2430298A1 (en) 2002-06-06
UY27042A1 (es) 2002-07-31
EP1337271A2 (en) 2003-08-27
AP2001002360A0 (en) 2001-12-31
NO20032441L (no) 2003-07-03
EE200300248A (et) 2003-10-15
ATE281181T1 (de) 2004-11-15
AR031431A1 (es) 2003-09-24
HUP0302160A2 (hu) 2003-11-28
BG107774A (en) 2004-01-30
ES2230378T3 (es) 2005-05-01
SK6192003A3 (en) 2004-07-07
HUP0302160A3 (en) 2005-05-30
EA200300432A1 (ru) 2003-10-30
PL365927A1 (en) 2005-01-10
DOP2001000289A (es) 2003-02-15
SV2003000751A (es) 2003-01-13
OA12534A (en) 2006-06-05
HRP20030420A2 (en) 2004-08-31
ZA200303381B (en) 2004-04-30
WO2002043762A2 (en) 2002-06-06
WO2002043762A3 (en) 2003-03-13
DE60106968T2 (de) 2005-11-03

Similar Documents

Publication Publication Date Title
NO20032441D0 (no) Kombinasjon av GABA agonister og sorbitol-dehydrogenase inhibitorer
NO20032387L (no) Kombinasjon av GABA agonister og aldose reduktase inhibitorer
NO20032668L (no) Gyraseinhibitorer og anvendelser derav
DK1251848T3 (da) Gyraseinhibitorer og anvendelse deraf
NO20052469D0 (no) Inhibitorer av II-beta-hydroksysteroid-dehydrogenase type 1 og type 2.
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
NO20042229L (no) Type 4-fosfodiestemseinhibitorer og anvendelse derav
NO20014823L (no) Heterocyklus-holdige bifenyl-aP2-inhibitorer og metode
NO20026283L (no) Inhibitorer av kobberholdige aminosydaser
CY2015053I2 (el) Υδροξαμικα παραγωγα χρησιμα ως αναστολεις δεακετυλασης
NO20041582L (no) Antistoffinhibitorer av GDF-8 og anvendelse derav
GB0025782D0 (en) Use of inhibitors
NO20020343D0 (no) Kaspase-inhibitorer og anvendelse derav
IS6759A (is) Ný þíadíasól og oxadíasól og notkun þeirra sem fosfórdíesterasa-7 hindra
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
NO20015274L (no) ACE-2 inhiberende forbindelser og fremgangsmåter for anvendelse derav
DK1307263T3 (da) Hidtil ukendt anvendelse af lipaseinhibitorer
NO20033854D0 (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
NO20020326L (no) Sammensetning og anvendelse av en inhibitor av PPAR-delta-aktivitet
NO20014770L (no) Assosiasjon av NO-syntase-inhibitor(er) og metabolske antioksydanter
DK1130214T3 (da) Korrosionsinhibitorer
IL154927A0 (en) Combination of statins and sorbitol dehydrogenase inhibitors
DK1337271T3 (da) Kombination af GABA-agonister og sorbitoldehydrogenaseinhibitorer
SI1337271T1 (en) Combination of gaba agonists and sorbitol dehydrogenase inhibitors
DK1307761T3 (da) Fremgangsmåde til retningsbestemmelse og bestemmelsesapparat

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application